

Synthetic studies on glycosphingolipids from Protostomia phyla: total syntheses of glycosphingolipids from the parasite, *Echinococcus multilocularis*

Takeshi Yamamura,^a Noriyasu Hada,^a Asuka Kaburaki,^a
Kimiaki Yamano^b and Tadahiro Takeda^{a,*}

^aKyoritsu University of Pharmacy, Shibakoen 1-5-30, Minato-ku, Tokyo 105-8512, Japan

^bDepartment of Biology, Hokkaido Institute of Public Health, Kita-19, Nishi-12, Kita-ku, Sapporo 060-0819, Japan

Received 6 July 2004; accepted 21 September 2004

Abstract—Efficient and systematic syntheses of four neutral glycosphingolipids that have been isolated from the metacestodes of *Echinococcus multilocularis* have been achieved. A key step is the direct glycosylation of galactosyl donors using thioglycosides with benzoyl ceramide in the presence of *N*-iodosuccinimide (NIS)/TfOH, which gave the desired oligosaccharide derivatives. The fully protected glycosides **13**, **20**, **22** and **25** were deprotected to give four target glycosphingolipids (**1–4**).
© 2004 Elsevier Ltd. All rights reserved.

Keywords: Glycosphingolipids; *Echinococcus multilocularis*; Chemical synthesis; Benzoyl ceramide


1. Introduction

In our continuing studies to elucidate the mechanism of host–parasite interaction, we have synthesized glycosphingolipids from various parasites.^{1–4} Persat et al.^{5–7} found some novel glycosphingolipids, β -D-Galp-(1→6)- β -D-Galp-(1→1)-Cer (**1**), α -L-Fucp-(1→3)- β -D-Galp-(1→6)- β -D-Galp-(1→1)-Cer (**2**), β -D-Galp-(1→6)- β -D-Galp-(1→6)- β -D-Galp-(1→1)-Cer (**3**) and β -D-Galp-(1→6)-[α -L-Fucp-(1→3)]- β -D-Galp-(1→6)- β -D-Galp-(1→1)-Cer (**4**) in metacestodes of the parasite, *Echinococcus multilocularis*, which belongs to the class Cestoda. It is particularly interesting to note that these glycosphingolipids contain the unique structures of a β -D-Galp-(1→6)- β -D-Galp-core and a fucose residue and point to the functional importance of glycolipids in parasitism that are recognized by serum antibodies from different patients with alveolar hydatid disease.

In one of our previous papers we reported¹ the synthesis of four glycosphingolipid analogues containing 2-branched fatty alkyl residues in place of ceramide. Therefore, at this time we report the total synthesis of four glycosphingolipids. Excellent pioneering studies of the coupling of oligosaccharides with sphingolipids have been reported by Ogawa,^{8–11} Schmidt^{12–15} and Hasegawa.^{16–19} Reactions to couple the oligosaccharide and the sphingolipid employ a glycosyl imidate as the donor and an azidosphingosine as the acceptor in the presence of TMSOTf or BF₃OEt₂.^{12–19} The coupling with azidosphingosine is now popularly employed because of the good yield for coupling and the ability to accept a series of fatty acids as components of ceramide, although the resulting glycosyl azidosphingosine necessitates further transformation. Furthermore, the coupling of glycosyl fluorides as a donor with sphingolipids as an acceptor have been also reported by Ogawa¹¹ and Nicolaou.²⁰ However, no one has reported the coupling of a thioglycoside with sphingolipids except the instance with azidosphingosine by Wong²¹ and Danishefsky.²² We synthesized the four

* Corresponding author. Tel.: +81 03 5400 2696; fax: +81 03 5400 2556; e-mail: takeda-td@kyoritsu-ph.ac.jp

target glycolipids **1–4**, as a systematic, integrated approach for the synthesis of tetrasaccharides using thioglycoside derivatives at the reducing end of the oligosaccharide moiety. This is the first report of the glycosylation of a thioglycoside with sphingolipids.



2. Results and discussion

2.1. Syntheses of monosaccharide derivatives

Syntheses of the additional galactopyranosyl building blocks **8** were carried out as depicted in Scheme 1. 2-(Trimethylsilyl)ethyl 2,4-di-*O*-benzoyl-3-*O*-benzyl-6-*O*-levulinoyl- β -D-galactopyranoside (**6**) was prepared from known 2-(trimethylsilyl)ethyl β -D-galactopyranoside (**5**)²³ by regioselective benzylation of the in situ prepared stannylidene derivative with benzyl bromide and subsequent regioselective levulinoylation with levulinic acid, followed by benzoylation. Removal of the benzyl groups from **6** by catalytic hydrogenolysis over 10% Pd-C and


subsequent chloroacetylation gave compound **7**. For selective removal of the 2-(trimethylsilyl)ethyl (SE) group, **7** was treated²³ with trifluoroacetic acid in dichloromethane to give the 1-hydroxy compound, which, on further treatment²⁴ with trichloroacetonitrile in the

presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in dichloromethane, gave only the corresponding α -trichloroacetimidate **8**.


2.2. Systematic syntheses of the each of the glycosphingolipids

In this work, four kinds of target glycolipids **1–4** were synthesized by stepwise condensation of suitably protected monosaccharide units. A systematic plan for synthesis of these compounds was designed as shown in Schemes 1–5.


First, we chose compounds **11**, **17**, **19** and **24**, which were phenyl thioglycoside derivatives, as the intermedi-



Scheme 1. Reagents: (a) (i) Bu_2SnO , benzene, Bu_4NBr , BnBr , benzene; (ii) DCC, DMAP, LevOH, CH_2Cl_2 ; (iii) BzCl , Pyr., 71% three steps; (b) (i) H_2 , Pd-C, AcOH, 2:1 THF-MeOH; (ii) ClCH_2COCl , Pyr., CH_2Cl_2 , 88%; (c) (i) CF_3COOH , CH_2Cl_2 ; (ii) CCl_3CN , DBU, CH_2Cl_2 , 74%.




Scheme 2. Reagents: (a) TMSOTf, CH₂Cl₂, 91%; (b) NIS, TfOH, CH₂Cl₂, 44%; (c) NaOMe, 1:1 dioxane–MeOH, quant.




Scheme 3. Reagents: (a) TMSOTf, CH₂Cl₂, quant.; (b) thiourea, 6:1 pyr.–EtOH, 75%; (c) hydrazine acetate, 10:1 THF–MeOH, 88%; (d) TMSOTf, CH₂Cl₂, 92%.

ates. Glycosylation of **10**²⁵ with **9**²⁶ in the presence of trimethylsilyl triflate TMSOTf (cat.)²⁷ and 4A MS in dichloromethane gave the desired disaccharide **11** (91%) as evidenced by ¹H NMR spectroscopy (H-1' 4.91 ppm, *J* 7.9 Hz). For the other targets, the common donor **8** was chosen for compounds **17**, **19** and **24**, which were condensed with **10** under the agency of TMSOTf (cat) to yield disaccharide **14** (quant) as evidenced by ¹H NMR spectroscopy (H-1' 4.42 ppm, *J* 8.0 Hz). Selective removal of the chloroacetyl group in **14** with thio-

urea and 6:1 pyridine–ethanol gave the partially protected disaccharide derivative **15**. Glycosylation of **15** with phenyl 2,3,4-tri-*O*-benzyl-1-thio-β-L-fucopyranoside **18**²⁸ in the presence of NIS and TfOH²⁹ as the glycosyl promoter and 4A MS in dichloromethane gave the desired α-glycoside **19** in 72% yield. Significant signals of the fucose unit in the ¹H NMR spectrum showed a signal for the anomeric hydrogen atoms at δ 5.05 (d, *J* 2.0 Hz). The α-L configuration of the newly formed glycosidic bond was also indicated



Scheme 4. Reagents: (a) NIS, TfOH, CH_2Cl_2 , 72%; (b) NIS, TfOH, CH_2Cl_2 , 54%; (c) H_2 , Pd-C, 2:1 THF-MeOH, 84%; (d) NaOMe, 1:1 dioxane-MeOH, 73%.



Scheme 5. Reagents: (a) NIS, TfOH, CH_2Cl_2 , 33%; (b) NaOMe, 1:1 dioxane-MeOH, quant.; (c) thiourea, 6:1 Pyr.-EtOH, 84%; (d) NIS, TfOH, CH_2Cl_2 , 91%; (e) NIS, TfOH, CH_2Cl_2 , 27%; (f) H_2 , Pd-C, 2:1 THF-MeOH, 98%; (g) NaOMe, 1:1 dioxane-MeOH, 94%.

by the $J_{C,H}$ value³⁰ of 169.7 Hz in the ¹³C NMR spectrum.

Compound **14** was converted by *O*-delevulinoylation using hydrazine acetate and condensed with **9** in the presence of TMSOTf as described for compound **11** to give the trisaccharide **17** (92%), as evidenced by ¹H NMR spectroscopy (H-1'' 4.63 ppm, *J* 7.9 Hz). Removal of the 3'-*O*-chloroacetyl group from **17** by thiourea gave the acceptor **23** (84%) for the tetrasaccharide derivative. Furthermore the glycosylation of **23** with **18** in the presence of NIS/TfOH as described for **19** gave the tetrasaccharide derivative **24** (91%), as evidenced by ¹H NMR spectroscopy (H-1 of Fuc 5.06 ppm, *J* 3.7 Hz).

Next, compounds **11**, **17**, **19** and **24** were used as glycosyl donors without further conversion. Glycosylation of benzoylceramide **12**³¹ with the each glycosyl donors, which was carried out in the presence of NIS/TfOH and 4A MS, afforded the desired β-glycosides **13** (44%), **20** (54%), **22** (33%) and **25** (27%). Removal of the benzyl groups from **20** and **25** by catalytic hydrogenolysis over 10% Pd-C in THF-MeOH gave **21** and **26**, and subsequent deacylation of **13**, **21**, **22** and **26** with sodium methoxide in 1:1 methanol-1,4-dioxane afforded the desired target glycolipids **1–4**.

In conclusion, a stereocontrolled, efficient route to the *Echinococcus* glycosphingolipids was exploited by use of phenyl thioglycosides as key glycosyl donors.

Biological testing results from studies of the sera from patients with alveolar hydatid disease for these compounds will be reported in detail elsewhere.

3. Experimental

3.1. General

Optical rotations were determined with a Jasco digital polarimeter. ¹H NMR and ¹³C NMR spectra were recorded with a JNM A 500 FT NMR spectrometer with Me₄Si as the internal standard for solutions in CDCl₃. MALDI-TOFMS was recorded on a Perceptive Voyager RP mass spectrometer. High-resolution mass spectra were recorded on a JEOL JMS-700 under FAB conditions. TLC was performed on Silica Gel 60-F₂₅₄ (E. Merck) with detection by quenching of UV fluorescence and by spraying with 10% H₂SO₄. Column chromatography was carried out on Silica Gel 60 (E. Merck). 2-(Trimethylsilyl)ethyl β-D-galactopyranoside (**5**), 2,3,4,6-tetra-*O*-benzoyl-α-D-galactopyranosyl trichloroacetimidate (**9**), phenyl 2,3,4-tri-*O*-benzoyl-1-thio-β-D-galactopyranoside (**10**) and phenyl 2,3,4-tri-*O*-benzyl-1-thio-β-L-fucopyranoside (**18**) were prepared by literature methods.^{23,25,26,28} Benzoylceramide **12** was prepared from *N*-palmitoyl-D-erythro-sphingosine, which was purchased from Acros Organics (Belgium) by the conventional four-step procedure.³¹

3.2. 2-(Trimethylsilyl)ethyl 2,4-di-*O*-benzoyl-3-*O*-benzyl-6-*O*-levulinoyl-β-D-galactopyranoside (**6**)

A mixture of 2-(trimethylsilyl)ethyl β-D-galactopyranoside (**5**) (2.00 g, 7.13 mmol), dibutyltin oxide (1.93 g, 7.75 mmol) and 150 mL of dry benzene was stirred under reflux for 5 h. Benzene (75 mL) was distilled off, and the solution was cooled to 60 °C and treated with Bu₄NBr (2.86 g, 8.87 mmol) and BnBr (1.73 mL, 14.7 mmol). The reaction mixture was stirred for 4.5 h, and the solution was concentrated. Purification of the residue by column chromatography (20:1 CHCl₃-MeOH) on silica gel gave 2-(trimethylsilyl)ethyl 3-*O*-benzyl-β-D-galactopyranoside (2.60 g, quant). To a solution of this compound (201 mg, 0.54 mmol) in CH₂Cl₂ (2 mL) was added levulinic acid (61 μL, 0.60 mmol), DCC (202 mg, 0.98 mmol) and DMAP (20 mg, 0.16 mmol). The reaction mixture was stirred for 3 h at rt, then extracted with CHCl₃, washed with 5% HCl, dried (MgSO₄), and concentrated. The crude product was purified by silica gel column chromatography using 35:1 CHCl₃-MeOH as eluent to give 2-(trimethylsilyl)ethyl 3-*O*-benzyl-6-*O*-levulinoyl-β-D-galactopyranoside (223 mg, 87.7%). To a solution of this compound (223 mg, 0.48 mmol) in pyridine (2 mL) was added benzoyl chloride (0.22 mL, 1.90 mmol), and the mixture was stirred for 2 h, then extracted with CHCl₃, washed with 5% HCl, aq NaHCO₃ and water, dried (MgSO₄) and concentrated. The product was purified by silica gel column chromatography using 20:1 toluene-acetone as eluent to give compound **6** (264 mg, 82.0%). $[\alpha]_D^{24} +83.5$ (*c* 0.8, CHCl₃); ¹H NMR (CDCl₃): δ 8.24–7.14 (m, 15H, Ph×3), 5.92 (d, 1H, *J*_{3,4} 3.1 Hz, *H*-4), 5.57 (dd, 1H *J*_{1,2} 7.9 Hz, *J*_{2,3} 9.8 Hz, *H*-2), 4.77 and 4.60 (each d, 2H, *J*_{gem} 12.8 Hz, benzyl methylene), 4.68 (d, 1H, *H*-1), 4.44 (dd, 1H, *J*_{5,6a} 6.7 Hz, *J*_{6a,6b} 11.0 Hz, *H*-6a), 4.27 (dd, 1H, *J*_{5,6b} 6.7 Hz, *H*-6b), 4.11–4.06 (m, 1H, -OCH₂CH₂-), 4.03 (t, 1H, *H*-5), 3.85 (dd, 1H, *H*-3), 3.68–3.62 (m, 1H, -OCH₂CH₂-), 2.85 (t, 2H, -OCOCH₂CH₂COCH₃), 2.65 (t, 2H, -OCOCH₂CH₂COCH₃), 2.29 (s, 3H, -OCOCH₂CH₂COCH₃), 1.02–0.93 (m, 2H, -OCH₂CH₂-), -0.09 (s, 9H, -Si(CH₃)₃); ¹³C NMR (CDCl₃): δ 206.6, 172.3, 165.9, 137.3, 133.3, 130.1, 129.9, 129.4, 128.5, 128.2, 128.0, 127.6, 101.0, 76.1, 71.2, 70.9, 70.7, 67.5, 66.4, 62.1, 38.0, 29.8, 27.9, 17.9. MALDI-TOFMS: Calcd for C₃₇H₄₄O₁₀Si: *m/z* 676. Found: *m/z* 699 [M+Na]⁺. HRFABMS: Calcd for C₃₇H₄₄O₁₀SiNa [M+Na]⁺: *m/z* 699.2601. Found: *m/z* 699.2648.

3.3. 2-(Trimethylsilyl)ethyl 2,4-di-*O*-benzoyl-3-*O*-chloroacetyl-6-*O*-levulinoyl-β-D-galactopyranoside (**7**)

A solution of **6** (1.41 g, 2.08 mmol) in 2:1 THF-MeOH (15 mL) was hydrogenolyzed in the presence of 10% Pd-C (500 mg) for 4 h at rt, then filtered and concentrated. The product was purified by silica gel column

chromatography using 5:1 toluene–acetone as eluent to give 2-(trimethylsilyl)ethyl 2,4-di-*O*-benzoyl-6-*O*-levulinoyl- β -D-galactopyranoside (1.20 g, quant). To a solution of this compound (349 mg, 0.595 mmol) in CH_2Cl_2 (1 mL) was added ClCH_2COCl (0.10 mL, 1.26 mmol) and pyridine (0.10 mL). The reaction mixture was stirred for 2 h at rt, then extracted with CHCl_3 , washed with 5% HCl, aq NaHCO_3 and water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 30:1 toluene–acetone as eluent to give compound **7** (354 mg, 89.7%). $[\alpha]_{\text{D}}^{24} +37.6$ (*c* 1.0, CHCl_3); ^1H NMR (CDCl_3): δ 8.19–7.33 (m, 10H, Ph \times 2), 5.77 (d, 1H, $J_{3,4}$ 3.1 Hz, *H*-4), 5.63 (dd, 1H, $J_{1,2}$ 7.9 Hz, *H*-2), 5.45 (dd, 1H, $J_{2,3}$ 10.4 Hz, *H*-3), 4.80 (d, 1H, *H*-1), 4.44 (dd, 1H, $J_{5,6a}$ 6.7 Hz, $J_{6a,6b}$ 11.6 Hz, *H*-6a), 4.24 (dd, 1H, $J_{5,6b}$ 6.7 Hz, *H*-6b), 4.17 (t, 1H, *H*-5), 4.13–4.07 (m, 1H, $-\text{OCH}_2\text{CH}_2-$), 3.97–3.88 (each d, 2H, J_{gem} 15.3 Hz, $\text{ClCH}_2\text{CO}-$), 3.72–3.67 (m, 1H, $-\text{OCH}_2\text{CH}_2-$), 2.79 (t, 2H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 2.61 (t, 2H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 2.24 (s, 3H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 1.03–0.92 (m, 2H, $-\text{OCH}_2\text{CH}_2-$), -0.09 (s, 9H, $-\text{Si}(\text{CH}_3)_3$); ^{13}C NMR (CDCl_3): δ 206.3, 172.1, 166.8, 165.9, 165.0, 133.7, 133.3, 130.0, 129.7, 129.3, 128.7, 128.6, 128.4, 100.9, 73.0, 70.7, 69.4, 67.8, 67.6, 61.5, 40.4, 37.8, 29.7, 27.8, 18.0. MALDI-TOFMS: Calcd for $\text{C}_{32}\text{H}_{39}\text{ClO}_{11}\text{Si}$: *m/z* 662. Found: *m/z* 685 $[\text{M}+\text{Na}]^+$. HRFABMS: Calcd for $\text{C}_{32}\text{H}_{39}\text{ClO}_{11}\text{SiNa}$ $[\text{M}+\text{Na}]^+$: *m/z* 685.1848. Found: *m/z* 685.1855.

3.4. 2,4-Di-*O*-benzoyl-3-*O*-chloroacetyl-6-*O*-levulinoyl- α -D-galactopyranosyl trichloroacetimidate (**8**)

To a solution of **7** (84 mg, 0.13 mmol) in CH_2Cl_2 (1 mL) cooled to 0°C was added CF_3COOH (1 mL), and the mixture was stirred for 2 h at rt and concentrated. EtOAc and toluene (1:2) were added and then evaporated to give the 1-hydroxy compound. To a solution of the residue in CH_2Cl_2 (2 mL) cooled at 0°C were added trichloroacetonitrile (0.27 mL, 2.69 mmol) and DBU (30.0 μL , 0.20 mmol). The mixture was stirred for 1 h at 0°C. After completion of the reaction, the mixture was concentrated. Column chromatography (30:1 toluene–acetone) of the residue on silica gel gave **8** (66 mg, 73.7%) as an amorphous mass. $[\alpha]_{\text{D}}^{24} +122.0$ (*c* 0.5, CHCl_3); ^1H NMR (CDCl_3): δ 8.65 (s, 1H, NH), 8.11–7.26 (m, 10H, Ph \times 2), 6.84 (d, 1H, $J_{1,2}$ 7.9 Hz, *H*-1), 5.87 (d, 1H, $J_{3,4}$ 3.1 Hz, *H*-4), 5.84 (dd, 1H, $J_{2,3}$ 11.0 Hz, *H*-3), 5.74 (dd, 1H, *H*-2), 4.64 (t, 1H, $J_{5,6b}$ $J_{5,6a}$ 6.1 Hz, *H*-5), 4.29 (dd, 1H, $J_{6a,6b}$ 11.0 Hz, *H*-6a), 4.24 (dd, 1H, *H*-6b), 3.96–3.88 (each d, 2H, J_{gem} 15.3 Hz, $\text{ClCH}_2\text{CO}-$), 2.69 (t, 2H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 2.53 (t, 2H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 2.15 (s, 3H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$); ^{13}C NMR (CDCl_3): δ 206.2, 172.1, 166.7, 165.8, 165.5, 160.6, 134.0, 133.8, 130.0, 129.9, 128.8, 128.7, 128.6, 93.5 (C-1), 69.6 (C-2),

69.3 (C-5), 68.0 (C-4), 67.5 (C-3), 61.6 (C-6), 40.4, 37.8, 29.8, 27.7. HRFABMS: Calcd for $\text{C}_{29}\text{H}_{27}\text{Cl}_4\text{NO}_{11}\text{Na}$ $[\text{M}+\text{Na}]^+$: *m/z* 728.0236. Found: *m/z* 728.0266.

3.5. Phenyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl-1-thio- β -D-galactopyranoside (**11**)

To a solution of **9** (190 mg, 0.26 mmol) and **10** (100 mg, 0.17 mmol) in dry CH_2Cl_2 (3 mL) was added powdered 4A MS (300 mg), and the mixture was stirred for 2 h at rt, then cooled to 0°C. TMSOTf (46 μL , 0.25 mmol) was added to the mixture, which was stirred for 1 h at 0°C, then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 70:1 toluene–acetone as eluent to give **11** (181 mg, 91.0%). $[\alpha]_{\text{D}}^{24} +235.3$ (*c* 0.3, 1 CHCl_3); ^1H NMR (CDCl_3): δ 8.11–7.20 (m, 40H, Ph \times 8), 5.95 (d, 1H, $J_{3',4'}$ 3.7 Hz, *H*-4'), 5.91 (d, 1H, $J_{3,4}$ 3.7 Hz, *H*-4), 5.79 (dd, 1H, $J_{1',2'}$ 7.9 Hz, $J_{2',3'}$ 10.4 Hz, *H*-2'), 5.68 (t, 1H, $J_{1,2}$ 10.4 Hz, $J_{2,3}$ 10.4 Hz, *H*-2), 5.57 (dd, 1H, *H*-3'), 5.51 (dd, 1H, *H*-3), 4.91 (d, 1H, *H*-1'), 4.89 (d, 1H, *H*-1), 4.41 (dd, 1H, $J_{5',6'b}$ 6.1 Hz, $J_{6'a,6'b}$ 11.0 Hz, *H*-6'a), 4.27–4.21 (m, 3H, *H*-5, *H*-5', *H*-6'b), 4.09 (dd, 1H, $J_{5,6a}$ 4.9 Hz, $J_{6a,6b}$ 11.0 Hz, *H*-6a), 3.96 (dd, 1H, $J_{5,6b}$ 4.9 Hz, *H*-6b); ^{13}C NMR (CDCl_3): δ 165.9, 165.5, 165.4, 165.2, 165.1, 134.1, 133.6, 133.5, 133.5, 133.4, 133.2, 133.1, 130.9, 130.1, 130.1, 129.8, 129.8, 129.3, 129.0, 129.0, 128.9, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 101.2 (C-1'), 85.3 (C-1), 76.8 (C-5), 73.0 (C-3), 71.7 (C-3'), 71.3 (C-5'), 69.7 (C-2'), 68.5 (C-4), 67.9 (C-6), 67.8 (C-4'), 67.7 (C-2), 61.7 (C-6'). MALDI-TOFMS: Calcd for $\text{C}_{67}\text{H}_{54}\text{O}_{17}\text{S}$: *m/z* 1162. Found: *m/z* 1185 $[\text{M}+\text{Na}]^+$.

3.6. 2,3,4,6-Tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-3-*O*-benzoyl-2-hexadecanamido-octadecane-1,3-diol (**13**)

To a solution of **11** (50 mg, 43.0 μmol) and **12** (33 mg, 51.2 μmol) in dry CH_2Cl_2 (1.5 mL) was added powdered 4A MS (150 mg), and the mixture was stirred for 2 h at rt, then cooled to -40°C . NIS (15 mg, 66.7 μmol) and TfOH (1.5 μL , 17.0 μmol) were added to the mixture, which was stirred for 2 h at -40°C , then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 20:1 toluene–EtOAc as eluent to give **13** (32 mg, 43.9%). $[\alpha]_{\text{D}}^{24}$

+69.2 (*c* 0.8, CHCl₃); ¹H NMR (CDCl₃) δ: 4.55 (d, 1H, *J*_{1',2'} 7.3 Hz, *H*-1'), 4.41 (d, 1H, *J*_{1,2} 7.9 Hz, *H*-1). MALDI-TOFMS: Calcd for C₁₀₂H₁₁₉NO₂₁: *m/z* 1693. Found: *m/z* 1716 [M+Na]⁺.

3.7. β-D-Galactopyranosyl-(1→6)-β-D-galactopyranosyl-(1→1)-(2*S*,3*R*)-2-hexadecanamido-octadecane-1,3-diol (**1**)

To a solution of **12** (32 mg, 18.9 μmol) in 1:1 MeOH–1,4-dioxane (2 mL) was added NaOMe (40 mg), and the mixture was stirred overnight at rt, then neutralized with Amberlite IR-120 (H⁺) resin. The resin was filtered off and washed with 1:1 CHCl₃–MeOH. The filtrate and washings were combined and concentrated. Column chromatography (1:1 CHCl₃–MeOH) of the residue on Sephadex LH-20 gave **1** (16 mg, quant). [α]_D²⁴ +6.8 (*c* 0.6, 1:1 CHCl₃–MeOH); ¹H NMR (49:1 DMSO-*d*₆–D₂O) δ: 4.15 (d, 1H, *J*_{1',2'} 7.3 Hz, *H*-1'), 4.07 (d, 1H, *J*_{1,2} 7.3 Hz, *H*-1). MALDI-TOFMS: Calcd for C₄₆H₈₉NO₁₃: *m/z* 863. Found: *m/z* 886 [M+Na]⁺. HRFABMS: Calcd for C₄₆H₈₉NO₁₃Na [M+Na]⁺: *m/z* 886.6232. Found: *m/z* 886.6153.

3.8. Phenyl 2,4-di-*O*-benzoyl-3-*O*-chloroacetyl-6-*O*-levulinoyl-β-D-galactopyranosyl-(1→6)-2,3,4-tri-*O*-benzoyl-1-thio-β-D-galactopyranoside (**14**)

To a solution of **8** (140 mg, 0.20 mmol) and **10** (77 mg, 0.13 mmol) in dry CH₂Cl₂ (2 mL) was added powdered 4A MS (300 mg), and the mixture was stirred for 2 h at rt, then cooled to 0 °C. TMSOTf (7.2 μL, 39.8 μmol) was added to the mixture, which was stirred for 30 min at 0 °C, then neutralized with Et₃N. The solids were filtered off and washed with CHCl₃. The combined filtrate and washings were successively washed with water, dried (MgSO₄) and concentrated. The product was purified by silica gel column chromatography using 15:1 toluene–acetone as eluent to give **14** (145 mg, quant). [α]_D²⁴ +96.3 (*c* 0.3, CHCl₃); ¹H NMR (CDCl₃) δ: 8.14–7.20 (m, 30H, Ph×6), 5.84 (d, 1H, *J*_{3,4} 3.7 Hz, *H*-4), 5.67–5.64 (m, 2H, *H*-2, *H*-4'), 5.58 (dd, 1H, *J*_{1',2'} 7.9 Hz, *J*_{2',3'} 10.4 Hz, *H*-2'), 5.46 (dd, 1H, *J*_{2,3} 9.8 Hz, *H*-3), 5.35 (dd, 1H, *H*-3'), 4.90 (d, 1H, *J*_{1,2} 9.8 Hz, *H*-1), 4.82 (d, 1H, *H*-1'), 4.27 (dd, 1H, *J*_{5',6a'} 4.9 Hz, *J*_{6a',6b'} 7.32 Hz, *H*-6a'), 4.12–3.94 (m, 5H, *H*-5, *H*-5', *H*-6a, *H*-6b, *H*-6b'), 3.91–3.83 (each d, 2H, *J*_{gem} 15.3 Hz, ClCH₂CO–), 2.72 (t, 2H, –OCOCH₂CH₂COCH₃), 2.49 (dd, 2H, –OCOCH₂CH₂COCH₃), 2.17 (s, 3H, –OCOCH₂CH₂COCH₃); ¹³C NMR (CDCl₃) δ: 147.3, 134.0, 133.8, 133.5, 133.3, 130.2, 129.9, 129.8, 129.8, 129.4, 129.1, 128.9, 128.8, 128.5, 128.4, 128.2, 113.0, 109.3, 101.4 (C-1'), 91.8, 85.4 (C-1), 76.8 (C-5), 73.1 (C-3), 72.9 (C-3'), 71.0 (C-5'), 69.3 (C-2'), 68.7 (C-4), 68.5 (C-6), 67.9 (C-4'), 67.6 (C-2), 61.5 (C-6'), 52.2, 48.3, 40.4, 38.0, 30.9, 29.7, 27.9, 22.7, 22.0, 11.9. MAL-

DI-TOFMS: Calcd for C₆₀H₅₃ClO₁₈S: *m/z* 1128. Found: *m/z* 1151 [M+Na]⁺. HRFABMS: Calcd for C₆₀H₅₄ClO₁₈S [M+H]⁺: *m/z* 1129.2719. Found: *m/z* 1129.2684.

3.9. Phenyl 2,4-di-*O*-benzoyl-6-*O*-levulinoyl-β-D-galactopyranosyl-(1→6)-2,3,4-tri-*O*-benzoyl-1-thio-β-D-galactopyranoside (**15**)

To a solution of **14** (50 mg, 44.2 μmol) in 6:1 pyridine–EtOH (3.5 mL) was added thiourea (34 mg, 0.45 mmol), and the mixture was stirred for 1 h at rt. The mixture was diluted with CHCl₃, washed with NaHCO₃ and water, dried (MgSO₄) and concentrated. The product was purified by silica gel column chromatography using 7:1 toluene–acetone as eluent to give **15** (35 mg, 75.1%). [α]_D²⁴ +132.0 (*c* 0.3, CHCl₃); ¹H NMR (CDCl₃) δ: 8.13–7.16 (m, 30H, Ph×6), 5.82 (d, 1H, *J*_{3,4} 3.1 Hz, *H*-4), 5.64 (t, 1H, *J*_{1,2} 9.8 Hz, *J*_{2,3} 10.4 Hz, *H*-2), 5.57 (d, 1H, *J*_{3',4'} 3.7 Hz, *H*-4'), 5.45 (dd, 1H, *H*-3), 5.29 (d, 1H, *J*_{1',2'} 7.9 Hz, *J*_{2',3'} 10.4 Hz, *H*-2'), 4.92 (d, 1H, *H*-1), 4.76 (d, 1H, *H*-1'), 4.31 (dd, 1H, *H*-5), 4.12–3.90 (m, 6H, *H*-3, *H*-5', *H*-6a, *H*-6b, *H*-6a', *H*-6b'), 2.70 (t, 2H, –OCOCH₂CH₂COCH₃), 2.49–2.41 (m, 2H, –OCOCH₂CH₂COCH₃), 2.13 (d, 1H, OH), 2.10 (s, 3H, –OCOCH₂CH₂COCH₃); ¹³C NMR (CDCl₃) δ: 172.4, 167.0, 166.2, 165.4, 165.2, 133.6, 133.4, 133.3, 133.1, 131.4, 130.1, 130.0, 129.9, 129.8, 129.7, 129.4, 129.0, 128.8, 128.6, 128.5, 128.4, 128.4, 128.20, 101.3 (C-1'), 85.4 (C-1), 76.7 (C-5), 73.7 (C-5'), 73.1 (C-3), 72.0 (C-3'), 71.3 (C-6), 70.4 (C-4'), 68.7 (C-2',C-4), 67.9 (C-2), 63.2 (C-6'), 38.0, 29.7, 27.9. MALDI-TOFMS: Calcd for C₅₈H₅₂O₁₇S: *m/z* 1052. Found: *m/z* 1075 [M+Na]⁺. HRFABMS: Calcd for C₅₈H₅₃O₁₇S [M+H]⁺: *m/z* 1053.3003. Found: *m/z* 1053.3073.

3.10. Phenyl 2,4-di-*O*-benzoyl-3-*O*-chloroacetyl-β-D-galactopyranosyl-(1→6)-2,3,4-tri-*O*-benzoyl-1-thio-β-D-galactopyranoside (**16**)

To a solution of **14** (50 mg, 44.3 μmol) in 2:1 MeOH–THF (1.7 mL) was added hydrazine acetate (4.08 mg, 44.3 μmol), and the mixture was stirred for 3 h at rt. The mixture was diluted with CHCl₃, washed with aq NaHCO₃ and water, dried (MgSO₄) and concentrated. The product was purified by silica gel column chromatography using 20:1 toluene–acetone as eluent to give **16** (40 mg, 87.6%). [α]_D²⁴ +97.4 (*c* 1.1, CHCl₃); ¹H NMR (CDCl₃) δ: 8.07–7.12 (m, 30H, Ph×6), 5.87 (d, 1H, *J*_{3,4} 3.1 Hz, *H*-4), 5.59–5.51 (m, 3H, *H*-2, *H*-2', *H*-4'), 5.41 (dd, 1H, *J*_{2,3} 9.8 Hz, *H*-3), 5.30 (dd, 1H, *J*_{2,3} 10.4 Hz, *J*_{3,4} 3.1 Hz, *H*-3'), 4.79 (d, 1H, *J*_{1,2} 9.8 Hz, *H*-1), 4.70 (d, 1H, *J*_{1',2'} 7.3 Hz, *H*-1'), 4.10 (t, 1H, *J*_{5,6b} 6.1 Hz, *J*_{5,6a} 5.5 Hz, *H*-5), 3.91 (dd, 1H, *J*_{6a,6b} 11.0 Hz, *H*-6a) 3.87–3.74 (m, 4H, *H*-5', *H*-6b, ClCH₂CO–), 3.55

(dd, 1H, $J_{5',6a'}$ 6.7 Hz, $J_{6a',6b'}$ 11.6 Hz, *H*-6a'), 3.38 (dd, 1H, $J_{5',6b'}$ 5.5 Hz, *H*-6b'), 2.09 (br s, 1H, OH); ^{13}C NMR (CDCl_3): δ 166.8, 166.6, 165.5, 165.3, 165.2, 165.1, 134.4, 133.9, 133.5, 133.5, 133.3, 133.2, 130.6, 130.2, 129.9, 129.7, 129.3, 129.1, 128.9, 128.8, 128.8, 128.7, 128.5, 128.4, 128.2, 101.3 (C-1'), 85.3 (C-1), 76.8 (C-5), 73.9 (C-5'), 73.1 (C-3), 72.9 (C-3'), 69.6 (C-2'), 68.5 (C-4), 68.2 (C-4'), 67.9 (C-2), 67.8 (C-6), 60.7 (C-6'), 40.4, 29.7. MALDI-TOFMS: Calcd for $\text{C}_{55}\text{H}_{47}\text{ClO}_{16}\text{S}$: m/z 1030. Found: m/z 1053 $[\text{M}+\text{Na}]^+$. HRFABMS: Calcd for $\text{C}_{55}\text{H}_{48}\text{ClO}_{16}\text{S}$ $[\text{M}+\text{H}]^+$: m/z 1031.2352. Found: m/z 1031.2356.

3.11. Phenyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,4-di-*O*-benzoyl-3-*O*-chloroacetyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl-1-thio- β -D-galactopyranoside (17)

To a solution of **16** (150 mg, 0.14 mmol) and **9** (162 mg, 0.22 μmol) in dry CH_2Cl_2 (3 mL) was added powdered 4A MS (300 mg), and the mixture was stirred for 2 h at rt, then cooled to 0°C. TMSOTf (7.8 μL , 43.1 μmol) was added to the mixture, which was stirred for 1 h at 0°C, then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 80:1 toluene–acetone as eluent to give **17** (215 mg, 91.8%). $[\alpha]_{\text{D}}^{24} +93.3$ (*c* 0.3, CHCl_3); ^1H NMR (CDCl_3): δ 8.12–7.20 (m, 50H, Ph \times 10), 5.89 (d, 1H, $J_{3,4}$ 3.1 Hz, *H*-4), 5.87 (d, 1H, $J_{3',4'}$ 3.1 Hz, *H*-4'), 5.78 (d, 1H, $J_{3'',4''}$ 3.1 Hz, *H*-4''), 5.67–5.32 (m, 6H, *H*-2, *H*-2', *H*-2'', *H*-3, *H*-3', *H*-3''), 4.88 (d, 1H, $J_{1,2}$ 9.8 Hz, *H*-1), 4.69 (d, 1H, $J_{1',2'}$ 7.9 Hz, *H*-1'), 4.63 (d, 1H, $J_{1'',2''}$ 7.3 Hz, *H*-1''), 4.15–3.54 (m, 11H, *H*-5, *H*-5', *H*-5'', *H*-6a, *H*-6b, *H*-6'a, *H*-6'b, *H*-6''a, *H*-6''b, ClCH_2CO –); ^{13}C NMR (CDCl_3): δ 166.6, 165.7, 165.5, 165.4, 165.3, 165.1, 165.0, 163.4, 134.0, 133.6, 133.3, 133.2, 130.9, 130.1, 130.0, 129.9, 129.8, 129.7, 129.7, 129.3, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.6, 128.5, 128.4, 128.3, 128.2, 128.2, 100.9, 100.5, 76.7, 73.0, 72.8, 71.9, 71.5, 71.0, 69.8, 69.4, 68.4, 67.8, 67.7, 67.2, 65.6, 61.2, 40.5. MALDI-TOFMS: Calcd for $\text{C}_{89}\text{H}_{73}\text{ClO}_{25}\text{S}$: m/z 1608. Found: m/z 1631 $[\text{M}+\text{Na}]^+$.

3.12. Phenyl 2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2,4-di-*O*-benzoyl-6-*O*-levulinoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl-1-thio- β -D-galactopyranoside (19)

To a solution of **15** (100 mg, 86.7 μmol) and **18** (100 mg, 190 μmol) in dry CH_2Cl_2 (2 mL) was added powdered 4A MS (200 mg), and the mixture was stirred for 2 h at rt, then cooled to -65°C . NIS (70 mg, 0.31 μmol) and TfOH (1.7 μL , 19 μmol) were added to the mixture,

which was stirred for 2 h at -65°C , then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 4:3 hexane–EtOAc as eluent to give **19** (100 mg, 78.5%). $[\alpha]_{\text{D}}^{24} +68.1$ (*c* 1.4, CHCl_3); ^1H NMR (CDCl_3): δ 8.15–6.94 (m, 45H, Ph \times 9), 5.83 (d, 1H, *H*-4), 5.70–5.60 (m, 3H, *H*-2', *H*-2, *H*-4'), 5.45 (dd, 1H, $J_{2,3}$ 9.8 Hz, *H*-3), 5.05 (d, 1H, $J_{1'',2''}$ 2.0 Hz, *H*-1''), 4.89 (d, 1H, $J_{1,2}$ 9.8 Hz, *H*-1), 4.81 and 4.49 (each d, 2H, J_{gem} 11.6 Hz, benzylic methylene), 4.76 (d, 1H, $J_{1',2'}$ 7.9 Hz, *H*-1'), 4.38–3.85 (m, 12H, benzylic methylene \times 2, *H*-6a, *H*-6b, *H*-6a', *H*-6b', *H*-3', *H*-5, *H*-5', *H*-5''), 3.78 (dd, 1H, $J_{2'',3''}$ 10.4 Hz, *H*-2''), 3.63 (dd, 1H, *H*-3''), 3.49 (s, 1H, *H*-4'), 2.74 (t, 2H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 2.52 (t, 2H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 2.13 (s, 3H, $-\text{OCOCH}_2\text{CH}_2\text{COCH}_3$), 1.01 (d, 3H, *H*-6''); ^{13}C NMR (CDCl_3): δ 206.8, 172.6, 166.3, 165.4, 165.3, 165.1, 164.8, 139.0, 138.6, 138.5, 133.8, 133.4, 133.4, 133.3, 133.1, 133.1, 130.2, 129.9, 129.9, 129.8, 129.7, 129.5, 129.4, 129.1, 128.9, 128.6, 128.5, 128.4, 128.4, 128.4, 128.2, 128.2, 128.1, 128.0, 127.5, 127.3, 127.2, 127.1, 101.9 (C-1'), 98.8 (C-1''), 85.4 (C-1), 78.9 (C-3''), 78.0 (C-4''), 76.8 (C-5), 75.2 (C-2''), 75.1 (C-3'), 74.7 (benzylic methylene), 73.3 (benzylic methylene), 73.1 (C-3), 72.0 (benzylic methylene), 71.9, 71.6, 69.9, 68.9 (C-4), 68.7 (C-6), 68.0 (C-2'), 67.7 (C-2), 62.5 (C-6'), 38.1, 29.7, 28.0, 16.4. MALDI-TOFMS: Calcd for $\text{C}_{85}\text{H}_{80}\text{O}_{21}\text{S}$: m/z 1468. Found: m/z 1491 $[\text{M}+\text{Na}]^+$.

3.13. 2,3,4-Tri-*O*-benzyl- α -L-fucopyranosyl-(1 \rightarrow 3)-2,4-di-*O*-benzoyl-6-*O*-levulinoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl- β -D-galactopyranosyl-(2*S*,3*R*)-3-*O*-benzoyl-2-hexadecan-amido-octadecane-1,3-diol (20)

To a solution of **19** (96 mg, 65 μmol) and **12** (87 mg, 0.14 μmol) in dry CH_2Cl_2 (2 mL) was added powdered AW300 MS (200 mg), and the mixture was stirred for 2 h at rt, then cooled to 0°C. NIS (23 mg, 102 μmol) and TfOH (3 μL , 34 μmol) were added to the mixture, which was stirred for 2 h at 0°C, then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 3:2 hexane–EtOAc as eluent to give **20** (70 mg, 53.5%). $[\alpha]_{\text{D}}^{24} +38.9$ (*c* 0.9, CHCl_3); ^1H NMR (CDCl_3): δ 5.08 (d, 1H, $J_{1'',2''}$ 3.7 Hz, *H*-1''), 4.55 (d, 1H, $J_{1',2'}$ 7.9 Hz, *H*-1'), 4.20 (d, 1H, $J_{1,2}$ 7.9 Hz, *H*-1). MALDI-TOFMS: Calcd for $\text{C}_{120}\text{H}_{147}\text{NO}_{25}$: m/z 2002. Found: m/z 2025 $[\text{M}+\text{Na}]^+$.

3.14. α -L-Fucopyranosyl-(1 \rightarrow 3)-2,4-di-*O*-benzoyl-6-*O*-levulinoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-3-*O*-benzoyl-2-hexadecanamido-octadecane-1,3-diol (21)

A solution of **20** (70 mg, 35 μ mol) in 2:1 THF–MeOH (4.5 mL) was hydrogenolyzed in the presence of 10% Pd–C (120 mg) overnight at rt, then filtered and concentrated. The product was purified by silica gel column chromatography using 60:1 CHCl₃–MeOH as eluent to give **21** (51 mg, 84.2%). $[\alpha]_D^{24} +91.1$ (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃): δ 4.93 (d, 1H, $J_{1'',2''}$ 3.7 Hz, *H*-1''), 4.64 (d, 1H, $J_{1',2'}$ 7.3 Hz, *H*-1'), 4.45 (d, 1H, $J_{1,2}$ 6.7 Hz, *H*-1). MALDI-TOFMS: Calcd for C₉₉H₁₂₉NO₂₅: *m/z* 1731. Found: *m/z* 1754 [M+Na]⁺.

3.15. α -L-Fucopyranosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 6)- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-2-hexadecanamido-octadecane-1,3-diol (2)

To a solution of **21** (26 mg, 15 μ mol) in 1:1 MeOH–1,4-dioxane (2 mL) was added NaOMe (20 mg), and the mixture was stirred overnight at rt, then neutralized with Amberlite IR-120 (H⁺) resin. The resin was filtered off and washed with 1:1 CHCl₃–MeOH. The filtrate and washings were combined and concentrated. Column chromatography (1:1 CHCl₃–MeOH) of the residue on Sephadex LH-20 gave **2** (11 mg, 72.6%). $[\alpha]_D^{24} +7.0$ (*c* 0.3, 1:1 CHCl₃–MeOH); ¹H NMR (49:1 DMSO-*d*₆–D₂O): δ 4.91 (d, 1H, $J_{1'',2''}$ 3.7 Hz, *H*-1''), 4.24 (d, 1H, $J_{1',2'}$ 7.9 Hz, *H*-1'), 4.07 (d, 1H, $J_{1,2}$ 7.3 Hz, *H*-1). MALDI-TOFMS: Calcd for C₅₂H₉₉NO₁₇: *m/z* 1009. Found: *m/z* 1032 [M+Na]⁺. HRFABMS: Calcd for C₅₂H₉₉NO₁₇Na [M+Na]⁺: *m/z* 1032.6811. Found: *m/z* 1032.6766.

3.16. 2,3,4,6-Tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,4-di-*O*-benzoyl-3-*O*-chloroacetyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-3-*O*-benzoyl-2-hexadecanamido-octadecane-1,3-diol (22)

To a solution of **17** (100 mg, 62.1 μ mol) and **12** (56 mg, 87 μ mol) in dry CH₂Cl₂ (1.5 mL) was added powdered 4A MS (200 mg), and the mixture was stirred for 2 h at rt, then cooled to 0 °C. NIS (28 mg, 0.12 mmol) and TfOH (2.8 μ L, 32 μ mol) were added to the mixture, which was stirred for 2 h at 0 °C, then neutralized with Et₃N. The solids were filtered off and washed with CHCl₃. The combined filtrate and washings were successively washed with aq Na₂S₂O₃ and water, dried (MgSO₄) and concentrated. The product was purified by silica gel column chromatography using 20:1 toluene–EtOAc as eluent to give **22** (44 mg, 33.0%). $[\alpha]_D^{24} +37.6$ (*c* 0.9, CHCl₃); ¹H NMR (CDCl₃): δ 4.62 (d, 1H, $J_{1',2'}$ 7.9 Hz, *H*-1'), 4.54 (d, 1H, $J_{1'',2''}$ 7.9 Hz, *H*-1''), 4.18 (d, 1H, $J_{1,2}$

7.9 Hz, *H*-1). MALDI-TOFMS: Calcd for C₁₂₄H₁₄₀ClNO₂₉: *m/z* 2141. Found: *m/z* 2164 [M+Na]⁺.

3.17. β -D-Galactopyranosyl-(1 \rightarrow 6)- β -D-galactopyranosyl-(1 \rightarrow 6)- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-2-hexadecanamido-octadecane-1,3-diol (3)

To a solution of **22** (35 mg, 16.3 μ mol) in 1:1 MeOH–1,4-dioxane (1 mL) was added NaOMe (40 mg), and the mixture was stirred overnight at rt, then neutralized with Amberlite IR-120 (H⁺) resin. The resin was filtered off and washed with 1:1 CHCl₃–MeOH. The filtrate and washings were combined and concentrated. Column chromatography (1:1 CHCl₃–MeOH) of the residue on Sephadex LH-20 gave **3** (17 mg, quant). $[\alpha]_D^{24} +9.2$ (*c* 0.4, CHCl₃); ¹H NMR (49:1 DMSO-*d*₆–D₂O): δ 4.17 (d, 1H, $J_{1',2'}$ 7.3 Hz, *H*-1'), 4.15 (d, 1H, $J_{1'',2''}$ 6.7 Hz, *H*-1''), 4.07 (d, 1H, $J_{1,2}$ 7.3 Hz, *H*-1). MALDI-TOFMS: Calcd for C₅₂H₉₉NO₁₈: *m/z* 1025. Found: *m/z* 1048 [M+Na]⁺. HRFABMS: Calcd for C₅₂H₉₉NO₁₈Na [M+Na]⁺: *m/z* 1048.6760. Found *m/z* 1048.6816.

3.18. Phenyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,4-di-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl-1-thio- β -D-galactopyranoside (23)

To a solution of **17** (256 mg, 159 μ mol) in 6:1 pyridine–EtOH (3 mL) was added thiourea (60 mg, 788 μ mol), and the mixture was stirred for 1 h at 60 °C. The mixture was diluted with CHCl₃, washed with NaHCO₃ and water, dried (MgSO₄) and concentrated. The product was purified by silica gel column chromatography using 20:1 toluene–acetone as eluent to give **23** (204 mg, 83.7%). $[\alpha]_D^{24} +86.5$ (*c* 0.5, CHCl₃); ¹H NMR (CDCl₃): δ 8.13–7.14 (m, 50H, Ph \times 10), 5.89 (d, 2H, $J_{3,4}$ 3.1 Hz, $J_{3'',4''}$ 3.1 Hz, *H*-4, *H*-4''), 5.72–5.50 (m, 5H, *H*-2, *H*-2'', *H*-3, *H*-3'', *H*-4'), 5.26 (dd, 1H, $J_{1',2'}$ 9.8 Hz, $J_{2',3'}$ 7.9 Hz, *H*-2'), 4.91 (d, 1H, $J_{1,2}$ 9.8 Hz, *H*-1), 4.65 (d, 1H, $J_{1'',2''}$ 9.8 Hz, *H*-1''), 4.63 (d, 1H, $J_{1',2'}$ 7.9 Hz, *H*-1'), 4.24–3.51 (m, 10H, *H*-3', *H*-5, *H*-5', *H*-5'', *H*-6a, *H*-6b, *H*-6'a, *H*-6'b, *H*-6''a, *H*-6''b); ¹³C NMR (CDCl₃): δ 166.6, 166.3, 165.8, 165.5, 165.3, 165.1, 165.0, 133.8, 133.6, 133.4, 133.3, 133.1, 131.2, 130.1, 129.9, 129.8, 129.7, 129.5, 129.3, 129.3, 129.0, 128.9, 128.79, 128.7, 128.6, 128.4, 128.4, 128.2, 128.2, 101.0, 100.8, 85.5, 76.7, 73.4, 73.0, 72.4, 71.8, 71.5, 71.1, 70.2, 69.8, 68.5, 67.9, 67.5, 66.8, 61.5. MALDI-TOFMS: Calcd for C₈₇H₇₂O₂₄S: *m/z* 1532. Found: *m/z* 1555 [M+Na]⁺.

3.19. Phenyl 2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-[2,3,4-tri-*O*-benzyl- α -L-fuco-pyranosyl-(1 \rightarrow 3)]-2,4-di-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl-1-thio- β -D-galactopyranoside (24)

To a solution of **23** (63 mg, 41.1 μ mol) and **18** (43 mg, 81.6 μ mol) in dry CH₂Cl₂ (1 mL) was added powdered

4A MS (100 mg), and the mixture was stirred for 2 h at rt, then cooled to -60°C . NIS (28 mg, 124 μmol) and TfOH (0.7 μL , 7.91 μmol) were added to the mixture, which was stirred for 1 h at -60°C , then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 10:1 toluene–EtOAc as eluent to give **24** (73 mg, 91.1%). $[\alpha]_{\text{D}}^{24} +36.1$ (c 0.9, CHCl_3); ^1H NMR (CDCl_3): δ 5.06 (d, 1H, $J_{1,2}$ 3.7 Hz, Fuc of $H-1$), 4.83 (d, 1H, $J_{1,2}$ 9.2 Hz, $H-1$), 4.68 (d, 1H, $J_{1',2'}$ 7.9 Hz, $H-1'$), 4.57 (d, 1H, $J_{1'',2''}$ 7.9 Hz, $H-1''$); ^{13}C NMR (CDCl_3): δ 101.3 (C-1'), 101.1 (C-1''), 98.5 (Fuc of C-1), 85.4 (C-1). MALDI-TOFMS: Calcd for $\text{C}_{114}\text{H}_{100}\text{O}_{28}\text{S}$: m/z 1948. Found: m/z 1971 $[\text{M}+\text{Na}]^+$.

3.20. 2,3,4,6-Tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-[2,3,4-tri-*O*-benzoyl- α -L-fucopyranosyl-(1 \rightarrow 3)]-2,4-di-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-3-*O*-benzoyl-2-hexadecanamido-octadecane-1,3-diol (25**)**

To a solution of **24** (68 mg, 34.9 μmol) and **12** (45 mg, 69.9 μmol) in dry CH_2Cl_2 (1.5 mL) was added powdered 4A MS (150 mg), and the mixture was stirred for 2 h at rt, then cooled to -40°C . NIS (16 mg, 71.1 μmol) and TfOH (1.6 μL , 18.1 μmol) were added to the mixture, which was stirred for 2 h at -40°C , then neutralized with Et_3N . The solids were filtered off and washed with CHCl_3 . The combined filtrate and washings were successively washed with aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (MgSO_4) and concentrated. The product was purified by silica gel column chromatography using 10:1 toluene–EtOAc as eluent to give **25** (23 mg, 26.6%). $[\alpha]_{\text{D}}^{24} +33.6$ (c 0.8, CHCl_3); ^1H NMR (CDCl_3): δ 5.10 (d, 1H, $J_{1,2}$ 3.7 Hz, Fuc of $H-1$), 4.68 (d, 1H, $J_{1',2'}$ 7.9 Hz, $H-1''$), 4.52 (d, 1H, $J_{1',2'}$ 7.3 Hz, $H-1'$), 4.16 (d, 1H, $J_{1,2}$ 7.3 Hz, $H-1$). MALDI-TOFMS: Calcd for $\text{C}_{149}\text{H}_{165}\text{NO}_{32}$: m/z 2482. Found: m/z 2506 $[\text{M}+\text{Na}]^+$.

3.21. 2,3,4,6-Tetra-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-[α -L-fucopyranosyl-(1 \rightarrow 3)]-2,4-di-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 6)-2,3,4-tri-*O*-benzoyl- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-3-*O*-benzoyl-2-hexadecanamido-octadecane-1,3-diol (26**)**

A solution of **25** (23 mg, 9.3 μmol) in 2:1 THF–MeOH (1.5 mL) was hydrogenolyzed in the presence of 10% Pd–C (40 mg) for 15 h at rt, then filtered and concentrated. The product was purified by silica gel column chromatography using 30:1 toluene–acetone as eluent to give **26** (20 mg, 97.6%). MALDI-TOFMS: Calcd for $\text{C}_{128}\text{H}_{149}\text{NO}_{32}$: m/z 2212. Found: m/z 2235 $[\text{M}+\text{Na}]^+$.

3.22. β -D-Galactopyranosyl-(1 \rightarrow 6)-[α -L-fucopyranosyl-(1 \rightarrow 3)]- β -D-galactopyranosyl-(1 \rightarrow 6)- β -D-galactopyranosyl-(1 \rightarrow 1)-(2*S*,3*R*)-2-hexadecanamido-octadecane-1,3-diol (4**)**

To a solution of **26** (20 mg, 9.04 μmol) in 1:1 MeOH–1,4-dioxane (1 mL) was added NaOMe (20 mg), and the mixture was stirred for 14 h at rt, then neutralized with Amberlite IR-120 (H^+) resin. The resin was filtered off and washed with 1:1 CHCl_3 –MeOH. The filtrate and washings were combined and concentrated. Column chromatography (1:1 CHCl_3 –MeOH) of the residue on Sephadex LH-20 gave **4** (10.0 mg, 94.4%). $[\alpha]_{\text{D}}^{24} -11.0$ (c 0.3, 1:1 CHCl_3 –MeOH); ^1H NMR (49:1 DMSO- d_6 – D_2O): δ 4.92 (d, 1H, $J_{1,2}$ 4.3 Hz, Fuc of $H-1$), 4.25 (d, 1H, $J_{1',2'}$ 7.3 Hz, $H-1''$), 4.16 (d, 1H, $J_{1',2'}$ 7.3 Hz, $H-1'$), 4.07 (d, 1H, $J_{1,2}$ 7.3 Hz, $H-1$). MALDI-TOFMS: Calcd for $\text{C}_{58}\text{H}_{109}\text{NO}_{22}$: m/z 1171. Found: m/z 1194 $[\text{M}+\text{Na}]^+$. HRFABMS: Calcd for $\text{C}_{58}\text{H}_{109}\text{NO}_{22}\text{Na}$ $[\text{M}+\text{Na}]^+$: m/z 1194.7339. Found: m/z 1194.7284.

Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research (No. 14771250) from the Ministry of Education, Science, Sports and Culture of Japan. The authors are grateful to Ms. J. Hada for providing NMR and MS data.

References

- Hada, N.; Hayashi, E.; Takeda, T. *Carbohydr. Res.* **1999**, *316*, 58–70.
- Hada, N.; Kuroda, M.; Takeda, T. *Chem. Pharm. Bull.* **2000**, *48*, 1160–1165.
- Ohtsuka, I.; Hada, N.; Ohtaka, H.; Sugita, M.; Takeda, T. *Chem. Pharm. Bull.* **2002**, *50*, 600–604.
- Ohtsuka, I.; Hada, N.; Sugita, M.; Takeda, T. *Carbohydr. Res.* **2003**, *337*, 2037–2047.
- Persat, F.; Bouhours, J.-F.; Mojon, M.; Petavy, A.-F. *J. Biol. Chem.* **1992**, *267*, 8764–8769.
- Persat, F.; Vuncent, C.; Mojon, M.; Petavy, A. F. *Parasitol. Immunol.* **1991**, *13*, 379–389.
- Persat, F.; Bouhours, J. F.; Mojon, M.; Francoise, A. *Mol. Biochem. Parasitol.* **1990**, *38*, 97–104.
- Ito, Y.; Numata, M.; Sugimoto, M.; Ogawa, T. *J. Am. Chem. Soc.* **1989**, *111*, 8508–8510.
- Numata, M.; Sugimoto, M.; Koike, K.; Ogawa, T. *Carbohydr. Res.* **1990**, *203*, 205–217.
- Numata, M.; Sugimoto, M.; Koike, K.; Ogawa, T. *Carbohydr. Res.* **1987**, *163*, 209–225.
- Nakano, T.; Ito, Y.; Ogawa, T. *Carbohydr. Res.* **1993**, *243*, 43–69.
- Zimmermann, P.; Greilich, U.; Schmidt, R. R. *Tetrahedron Lett.* **1990**, *31*, 1849–1852.
- Schmidt, R. R.; Bar, T.; Apell, H. J. *Angew. Chem., Int. Ed. Engl.* **1987**, *26*, 793–794.
- Lassaletta, J. M.; Carlsson, K.; Garegg, P. J.; Schmidt, R. R. *J. Org. Chem.* **1996**, *61*, 6873–6880.

15. Lassaletta, J. M.; Schmidt, R. R. *Tetrahedron Lett.* **1995**, *36*, 4209–4212.
16. Kiso, M.; Nakamura, A.; Tomida, T.; Hasegawa, A. *Carbohydr. Res.* **1986**, *158*, 101–111.
17. Murase, T.; Ishida, H.; Kiso, M.; Hasegawa, A. *Carbohydr. Res.* **1989**, *188*, 71–80.
18. Hotta, K.; Ishida, H.; Kiso, M.; Hasegawa, A. *J. Carbohydr. Chem.* **1995**, *14*, 491–506.
19. Kameyama, A.; Ehara, T.; Yamada, Y.; Ishida, H.; Kiso, M.; Hasegawa, A. *J. Carbohydr. Chem.* **1995**, *14*, 507–523.
20. Nicolaou, K. C.; Caulfield, T. J.; Katoaka, H. *Carbohydr. Res.* **1990**, *202*, 177–191.
21. Plettenburg, O.; Bodmer-Narkevitch, V.; Wong, C.-H. *J. Org. Chem.* **2002**, *67*, 4559–4564.
22. Deshpande, P. P.; Kim, H. M.; Zatorski, A.; Park, T. K.; Ragupathi, G.; Livingston, P. O.; Live, D.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1998**, *120*, 1600–1614.
23. Jansson, K.; Ahlfors, S.; Frejd, T.; Kihlberg, J.; Magnusson, G.; Dahmen, J.; Noori, G.; Stenvall, K. *J. Org. Chem.* **1988**, *53*, 5629–5647.
24. Schmidt, R. R.; Grundler, G. *Synthesis* **1981**, 885–887.
25. Marra, A.; Esnault, J.; Veyrieres, A.; Sinay, P. *J. Am. Chem. Soc.* **1992**, *114*, 6354–6360.
26. Rio, S.; Beau, J.-M.; Jacquinot, J.-C. *Carbohydr. Res.* **1991**, *219*, 71–90.
27. Schmidt, R. R. *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 212–235.
28. Komba, S.; Ishida, H.; Kiso, M.; Hasegawa, A. *Bioorg. Med. Chem.* **1996**, *4*, 1833–1847.
29. Konradsson, P.; Udodong, U. E.; Fraser-Reid, B. *Tetrahedron Lett.* **1990**, *31*, 4313–4316.
30. Bock, K.; Pedersen, C. *J. Chem. Soc., Perkin Trans. 2* **1974**, 293–297.
31. Koike, K.; Numata, M.; Sugimoto, M.; Nakahara, Y.; Ogawa, T. *Carbohydr. Res.* **1986**, *158*, 113–123.